Category: ACN Newswire

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - December 3, 2024) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") a leading North American exploration company focused on critical minerals, acknowledges today's announcement by China banning exports of gallium, germanium, and antimony to the United States. This move underscores the urgent need for Western nations to secure reliable long-term sources of these essential materials.Antimony, a critical component in military applications, energy storage, and advanced manufacturing, is now at the forefront of the global supply chain crisis. China's ban, coupled with existing restrictions that came into effect September 15, 2024, has already sent antimony prices soaring by over 228% this year(1). The Western world faces mounting pressure to address its reliance on China for strategic resources critical to national defense and technological innovation. This ban comes at a time when defense sector inventories are at already concerningly low levels.(2)Military Metals recent antimony mineral project acquisitions in Slovakia, Nova Scotia, and Nevada provide shareholders with a pure antimony play with a diverse portfolio in top jurisdictions."This announcement from China reinforces the importance of Military Metals' mission to secure a sustainable, independent future supply chain for critical minerals," said Scott Eldridge, CEO of Military Metals Corp. "The West can no longer afford to rely on adversarial nations for resources essential to our security and economic stability. We are taking proactive steps to meet this growing demand with future domestic and allied sources of antimony."As geopolitical tensions escalate and the trade war intensifies, Military Metals will continue to prioritize the development of critical mineral resources and work closely with governments and industry partners to ensure the West remains resilient and self-sufficient.About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.comFor enquiries, please call 604-722-5381 or 604-537-7556This news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release include exploration activities, and assumptions related to the continuation of the global demand for antimony. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include, geopolitical developments related to the supply of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the properties that are the subjects of this news release, the results of any future exploration activities, which cannot be guaranteed, and such other factors as may impact both and any future activities in respect of the properties.. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.(1)Reuters; China bans export of critical minerals to US as trade tensions escalate; By Amy Lv and Tony Munroe; December 3, 2024(2)Heritage Foundation: commentary/It’s Past Time to Re-Supply Our Munitions-Depleted U.S. Navy by Jim Fein; June 17, 2024To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232325 Copyright 2024 ACN Newswire via SeaPRwire.com.

London, UK, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - The 3rd edition of the London Climate Technology Show concluded last week, paving a vital roadmap towards fully decarbonising our planet through sustainable technologies. The event brought together policymakers, eco-technology leaders, industry professionals, and innovators, all unified in their call for an immediate shift to sustainable and green solutions to secure a better future for the planet.The two-day event opened on 27th November with an inspiring keynote by Felicity Burch, Executive Director of the Responsible Technology Adoption Unit at the Department for Science, Innovation, and Technology (DSIT), who spoke about AI Innovation in Clean Energy and the DSIT's Manchester Prize. Following her, Ing. Abigail Cutajar, CEO of the Climate Action Authority, talked about Pioneering the Surge Towards Climate and Energy Transitions.The conference unfolded over two dynamic days, featuring a packed agenda of insightful presentations and engaging panel discussions. It delved into actionable strategies for decarbonisation, advancements in AgriTech, the evolving carbon market, eco-funds, energy, CCS, built environment and other groundbreaking innovations in climate technology.Notable discussions highlighted the need for farmers to balance carbon stewardship with food production over the next few decades, the importance of consistent government policies to enable businesses to plan and innovate effectively, and the urgency of addressing digital and engineering skill shortages to ensure a successful green energy transition. Industry experts also called for common sustainability metrics to measure corporate efforts fairly, emphasized the value of collaboration over competition to accelerate the green transition, and underscored the need for farmers to access landscape-level data to enhance biodiversity.The exhibition hall featured groundbreaking innovations and solutions in sustainability and climate technology, including carbon capture and storage (CCS) from companies like CGI and Terra CO2 Technology, carbon management and accounting solutions by Greenly and Gaia Carbon Accounting, and emerging climate technologies from innovators such as Nabla Flow and Luna 9. Other exhibitors showcased AI-driven solutions, sustainable energy systems, and innovative carbon reduction technologies, presenting a comprehensive snapshot of the future of climate tech.#CTS24 also hosted interactive side events, including startup acceleration programs and hands-on workshops, providing participants with opportunities for learning, networking, and collaboration. These sessions empowered attendees to adopt transformative technologies and take decisive climate action.Attendee ExperiencesThe event received overwhelming positive feedback:Mark Haley, Co-founder of Cero3, shared, "We’re so proud to have unveiled our sustainable travel planner. The feedback and interest exceeded our expectations."Satyajit Mohanan, Projects and Business Development Coordinator at Cambridge Cleantech, remarked, "It was a pleasure to be part of this event. I met amazing people and look forward to the next edition."Dennis Chacko, Senior Sales Manager at the British Board of Agreement, shared his excitement over a unique sustainable pen: "Once used, you can plant it to grow something new—a powerful reminder of how everyday items can contribute to a greener future."As this successful edition concludes, the organisers are already planning for a bigger, more impactful 4th Edition, with expanded content and greater opportunities to drive meaningful change toward a sustainable future.For further information, please reach out to us at press@valiantandcompany.com. Copyright 2024 ACN Newswire via SeaPRwire.com.

深圳, 2024年12月2日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司（以下简称"康哲药业"）欣然宣布，于2024年12月2日，通过其全资附属公司与杭州新元素药业有限公司（以下称"新元素药业"，曾用名"江苏新元素医药科技有限公司"）就治疗痛风及高尿酸血症的1类新药ABP-671（"产品"）签订独家商业化协议（"协议"）。根据协议，康哲药业获得产品在中国大陆、香港特别行政区及澳门特别行政区的独家商业化权利。合作期限开始于协议生效之日，自产品首次在中国大陆获批上市起拥有十年的授权期限（"授权期限"）。授权期限届满后，根据协议约定的特定条件，授权期限可自动续期十年。ABP-671是用于治疗痛风及高尿酸血症的化药1类创新药，目前正分别在中国和境外开展关于痛风的2b/3期临床试验，产品通过抑制尿酸盐转运蛋白1（URAT1），降低肾脏对尿酸的重吸收。在已经完成的两项2期临床试验结果显示，ABP-671多个剂量组（1mg至12mg）表现出良好的药效和安全性。该产品2mg每天单次给药，其药效可能相当于或优于苯溴马隆和非布司他最高剂量80mg的药效。尿酸下降可维持全天候24小时，没有出现严重的安全性问题。产品有望为痛风及高尿酸血症患者带来疗效更优、安全性更高的治疗选择[1]。与ABP-671相关的化合物和用途方面的多个专利已在中国获得授权。高尿酸血症是指成人在正常嘌呤饮食情况下，非同日2次空腹血尿酸水平超过420μmol/L (7.0mg/dL)。高尿酸血症患者出现尿酸盐晶体沉积，导致痛风性关节炎，称为痛风。高尿酸血症及痛风可引起关节软骨、骨质、肾脏以及血管壁等急慢性炎症损伤，导致心、脑、肾等多器官损害。《2021中国高尿酸及痛风趋势白皮书》数据显示，我国高尿酸血症的总体的患病率为13.3%，高尿酸血症患病人数约1.77亿人，痛风总体发病率为1.1%，患病人数约为1,466万。据弗若斯特沙利文分析，未来中国高尿酸血症和痛风患病人数会持续增加，将在2030年分别达到2.4亿人、5,220万人。目前我国临床上常用的降尿酸药物主要包括抑制尿酸合成和促进尿酸排泄两类，由于已上市降尿酸药物在疗效和安全性上仍存在一定的局限性，如导致肾衰竭、心脏猝死或严重肝脏毒性等。中国痛风及高尿酸血症患者对高效安全的降尿酸药物仍然有迫切的需求。ABP-671是当前痛风及高尿酸血症治疗中潜在疗效优、安全性好的产品。通过本次合作引进，填补了康哲药业痛风治疗产品的空白。痛风及高尿酸血症既属于风湿疾病又属于慢性代谢性疾病，与康哲药业心脑血管/消化业务的战略布局，以及在售品种的网络资源高度契合。ABP-671如未来获批上市，在风湿免疫科可与在售产品美泰彤（甲氨蝶呤注射液），在内分泌科和骨科可与益盖宁（依降钙素注射液）在专家网络与市场资源方面协同。基于未满足的临床需求和产品预期扎实的临床数据，期待ABP-671的临床开发工作顺利推进，使相关适应症患者尽快从创新疗法中获益。关于新元素药业新元素药业创办于2012年3月，专注于代谢和炎症领域疾病中具有全球商业价值和全球竞争力的创新药的研发。新元素药业主要核心团队人员来自美国，具有广泛的创新药物的研发经验，过去几年新元素药业取得了显著的发展成果。其核心产品ABP-671正处于后期临床研发阶段，用于治疗慢性痛风；另一个小分子创新药物ABP-745用于抗炎自免领域适应症，已完成1期临床，表现出良好的PK和安全性，即将进入2期临床。有关新元素药业及其产品的更多信息，请访问其官方网站：https://www.atombp.com/。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化业务竞争力，并将皮肤医美、眼科业务独立运营，培育专科小领域的大龙头，提升专科规模效率。同时业务版图拓展至东南亚市场，着力成为全球药企进军东南亚市场的"桥头堡"，助力康哲药业高质量持续健康发展。参考文献：1.产品2期临床试验结果已发布，详情如下：https://www.atombp.com/2023/03/01/atom-bioscience-announces-positive-results-of-phase-2a-china-clinical-trial-of-its-urat1-inhibitor-for-chronic-gout/康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2024 亚太商讯 via SeaPRwire.com.

SAN DIEGO, CA, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - On November 19, 2024, General Atomics Aeronautical Systems, Inc. (GA-ASI) hosted its first Blue Magic Netherlands (BMN) event in Eindhoven, the Netherlands. Approximately 200 people attended the event that provided Dutch businesses with an opportunity to present their capabilities to GA-ASI and other companies interested in possible collaborations. GA-ASI was joined for the event by the Netherlands Ministry of Economic Affairs, the Netherlands Ministry of Defence, Lockheed Martin Ventures, Brainport Development, Brabant Development Agency (BOM), the Netherlands Industries for Defence & Security (NIDV), and SpaceNED.At this event, GA-ASI and its partners heard first-hand from Dutch companies about the important capabilities they are developing. The process started in July when GA-ASI put out an open invitation to Dutch businesses to apply for the opportunity to present innovative technologies at the November 19 event. Key areas of focus included Artificial Intelligence/Machine Learning, Autonomy, Advanced Materials, Sensors, Advanced Manufacturing, and Space. Close to 50 companies applied and after reviewing the applications, 15 businesses were selected to pitch their capabilities to an audience that included lightweight lattice structures, gas detection technologies, advanced battery and photonics applications, and several innovative unmanned system and AI applications, among many others."This event is where the rubber meets the road," said Brad Lunn, Managing Director-Strategic Finance at GA-ASI. "In addition to attracting many companies, we increased the areas of expertise and depth of knowledge from the presenting companies in order to provide research, development, and breakthrough innovations to support current and future missions by GA-ASI aircraft. We also wanted to give the companies an opportunity to pitch in front of other potential customers, partners, and investors."The first Blue Magic event held by GA-ASI was in 2019 in Belgium, with subsequent events held in 2020, 2021, and 2023. GA-ASI is delivering eight MQ-9A Remotely Piloted Aircraft to the Royal Netherlands Air Force (RNLAF).GA-ASI expects to announce technology partnerships stemming from the BMN event and intends to hold this event on an annual basis in the Netherlands.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable remotely piloted aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - December 2, 2024, In the context of the Belt and Road Initiative, the first Belt and Road Golden Route Series Financial Promotion Event——the Kyrgyz Republic Ministry of Finance's promotional seminar and non-deal roadshow was successfully held today in Hong Kong. The event was jointly hosted by TF International Securities Group Limited ("TF International") and China CITIC Bank International Limited ("China CITIC Bank International"), attracting numerous international investors and financial industry leaders.The Kyrgyz Republic, as one of the earliest countries to support and engage in the Belt and Road Initiative, has seen increasingly close economic and trade relations with China. Recently, TF International signed a memorandum of understanding with the Kyrgyz Republic Ministry of Finance, becoming the first Hong Kong-based Chinese securities firm to establish an official partnership with the Kyrgyz Republic Ministry of Finance. The two parties work together to promote the RMB internationalization, support the real economy, facilitate high-quality development, and reinforce Hong Kong’s position as an international financial center. The event featured distinguished guests, including Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of Kyrgyz Republic, Mr. Abdybapov Abdanbek Abdybapovich, Head of the Government Borrowing Department of Kyrgyz Republic, Mr. CHAN Ho Lim, Joseph, JP, Under Secretary for Financial Services and the Treasury of Hong Kong S.A.R., and Mr. ZOU Chuan, CEO of TF International, as well as Mr. Andy Siow, Senior Coverage Banker, DCM, at China CITIC Bank International. They shared insights into Kyrgyzstan’s development opportunities and investment prospects in the international financial market, discussing investment opportunities and key focus areas for mutually beneficial cooperation. In his opening speech, Mr. CHAN Ho Lim, Under Secretary for Financial Services and the Treasury of Hong Kong, remarked, "Hong Kong has firmly established itself as Asia’s leading international financial centre. Our core strengths include free flow of capital and information, a robust common law system, and a simple and low tax regime, and Hong Kong enjoys preferential access to Mainland China. All these position Hong Kong as the super-connector between China and international markets, which plays a key role in promoting RMB internationalization and advancing the Belt and Road Initiative. The Kyrgyz Republic is an important partner under the Belt and Road Initiative and is certainly Hong Kong’s important trading partner in Central Asia.” He also stated that, “I would like to express my gratitude to the Kyrgyz Republic Ministry of Finance and TF International and appreciate your commitment to fostering stronger ties between Central Asia and Hong Kong. We look forward to exploring potential future collaborations with the Kyrgyz Republic that will benefit our respective markets and promote partnerships among Belt and Road nations.” As of September 1, 2024, Renminbi (RMB) has been included in the list of official daily exchange rates published by Kyrgyzstan, alongside the US dollar, euro, Russian ruble, and Kazakh tenge. This move further strengthens economic and financial cooperation between the two countries. Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of the Kyrgyz Republic, stated, "The inclusion of the RMB in the list of official daily exchange rates in Kyrgyzstan marks a new stage in the economic cooperation between the two countries. This not only provides greater convenience for international investors but also empowers the development of Kyrgyzstan's financial market. Through this promotional event, we hope to connect with more international investment institutions and jointly promote the sustainable development of the regional economy." Hong Kong, as the international financial center and the central city of the Guangdong-Hong Kong-Macao Greater Bay Area, plays an important bridging role in the Belt and Road Initiative, leveraging its diverse financing channels and close alignment with national strategies. Mr. ZOU Chuan, CEO of TF International, stated, "The Belt and Road Initiative offers significant opportunities for economic integration and development, enhancing trade across Asia, Europe, the Middle East, and beyond. As a gateway between China and the world, Hong Kong is a key hub for the internationalization of the Renminbi, facilitating its use in trade and investment, and supporting effective currency risk management for BRI projects. With ongoing economic expansion and the internationalization of the Renminbi, Hong Kong is well-positioned to emerge as the premier financing hub. As we explore upcoming opportunities, I encourage you to envision the transformative impact these initiatives can have on the Kyrgyz Republic’s development agenda and the broader economic landscape of Central Asia. Together, we can unlock new avenues for growth and collaboration." From December 3 to 6, 2024, TF International, in collaboration with China CITIC Bank International will join forces with the Kyrgyz Republic Ministry of Finance in hosting a series of non-deal roadshows in Shanghai and Beijing, further strengthening ties with the Chinese financial market. The success of today’s promotional seminar and non-deal roadshow in Hong Kong marks a new milestone in the economic cooperation between the two countries and injects fresh momentum into the high-quality development of the Belt and Road Initiative. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年12月3日 - (亚太商讯 via SeaPRwire.com) - 2024年12月2日，在"一带一路"倡议的背景下，由天风国际证券集团有限公司（以下简称"天风国际"）与中信银行(国际)有限公司（以下简称"信银国际"）联合主办的首场"一带一路"黄金线系列金融推介会 - 吉尔吉斯斯坦国家财政部推介会暨非交易性路演于今日在香港圆满举行。本次活动吸引了众多国际投资机构及金融行业领袖出席。吉尔吉斯斯坦作为最早支持和参与"一带一路"倡议的国家之一，近年来与中国的经贸合作关系日益密切。近期，天风国际与吉尔吉斯斯坦国家财政部签订合作备忘录，成为首家与吉尔吉斯斯坦国家财政部建立合作关系的驻港中资券商。双方将就共同推动人民币国际化愿景，服务实体经济，助力高质量发展，为维持并进一步巩固香港作为国际金融中心的地位，展开更广泛的合作。本次活动邀请了多位重量级嘉宾，包括吉尔吉斯斯坦国家财政部副部长Amanbaev Umutzhan Mominovich先生、政府借贷部主任Abdybapov Abdanbek Abdybapovich先生、香港特别行政区政府财经事务及库务局副局长陈浩濂太平绅士，以及天风国际行政总裁邹传先生和信银国际高级董事、债券资本市场、财资及环球市场Andy Siow先生。会上，嘉宾们分享了吉尔吉斯斯坦在参与国际金融市场的发展机遇与其投资前景，共同探讨了双方互利共赢的合作着力点。陈浩濂副局长在致辞中表示："香港作为全球主要国际金融中心，具备资本与信息的自由流动、稳健的普通法制度以及单一税制等核心优势，同时香港与中国内地市场联系紧密，在促进人民币国际化和推动'一带一路'倡议中发挥着关键作用。而吉尔吉斯斯坦作为'一带一路'倡议下的重要合作伙伴，毫无疑问，也是香港在中亚地区的重要贸易伙伴。感谢天风国际的精心组织和吉尔吉斯斯坦代表团的到访，今天我们齐聚一堂，探讨如何进一步加强中亚与香港之间的经济合作。我们期待未来与吉尔吉斯斯坦的合作将为两国经济增长注入新的动力，推动'一带一路'国家之间的多层次合作，进一步促进区域经济的可持续发展。"自2024年9月1日起，人民币已正式列入吉尔吉斯斯坦官方每日公布汇率的货币名单，与美元、欧元、俄罗斯卢布和哈萨克斯坦坚戈一起，成为吉尔吉斯斯坦每日公布汇率的货币，这一举措进一步深化了两国在经济与金融领域的合作。吉尔吉斯斯坦国家财政部副部长Amanbaev Umutzhan Mominovich先生在会上表示："人民币成功纳入吉尔吉斯斯坦官方每日公布汇率的货币名单，标志着两国经济合作进入了新的阶段。这不仅为国际投资者提供了更多便利，也为吉尔吉斯斯坦的金融市场发展赋能。我们希望通过此次推介会，与更多国际投资机构建立联系，共同推动区域经济的可持续发展。"香港作为国际金融中心，同时也是粤港澳大湾区的核心城市，凭借多样的融资渠道和与国家战略的深度对接，在"一带一路"倡议中发挥了重要的桥梁作用。作为此次活动的联合主办方之一，天风国际行政总裁邹传先生在致辞中提到："'一带一路'倡议为经济一体化和发展提供了巨大机遇，推动亚欧、中东乃至更广泛地区的贸易往来。香港作为中国市场联通世界的重要窗口，同时也是人民币国际化的关键枢纽，促进人民币在贸易和投资中的使用，支持'一带一路'项目的融资与汇率风险管理。随着人民币国际化的推进，香港正稳步成为全球领先的融资中心。在探索未来机遇的同时，期待今日的活动与市场洞察的深入分享，对吉尔吉斯斯坦发展进程以及中亚经济带来积极、深远的影响。"后续，天风国际联合信银国际将陪同吉尔吉斯斯坦国家财政部于12月3日至6日期间，陆续在上海和北京继续举办系列非交易性路演活动，进一步深化吉尔吉斯斯坦与中国金融市场的联系。此次香港推介会的成功举办标志着两国在经济领域合作迈向新高度，为"一带一路"倡议的高质量发展注入了新动能。 Copyright 2024 亚太商讯 via SeaPRwire.com.

Highlights (relevant audited data for the year ended 31 August 2024)- Revenue increased by 17% YoY to approximately RMB2,312 million;- Gross profit rose by 10% YoY to approximately RMB1,124 million;- Profit for the period attributable to owners of the Company rose by 16% YoY to approximately RMB715 million;- Number of student enrolments increased by 11% YoY to approximately 95,600;- Payment of a final dividend of HK10.0 cents per share;- Dividend payout ratio of 30% for the year.HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - Edvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) has announced its audited FY2024 Annual Results for the year ended 31 August 2024 (the “Reporting Period”). During the Reporting Period, the Group actively responded to national policies, vigorously promoted industry-education integration, deepened the connotations of international education, continued to introduce unique new featured majors that match market and industry demands and fully embraced artificial intelligence (“AI”), succeeding in raising education quality and brand presence, thereby achieving steady growth in performance year after year.During the Reporting Period, the Group’s revenue totaled approximately RMB2,312 million, representing an increase of 17% as compared to the corresponding period of the preceding year. The increase was mainly attributable to the continuous enhancement of the Group’s education brand effectiveness, which drove a rise in the number of student enrolments and higher average tuition fees recorded by the Group’s domestic schools. Profit for the period attributable to owners of the Company rose by 16% YoY to approximately RMB715 million. The number of students enrolled in the Group’s schools continued to expand yearly, reaching approximately 95,600, with a year-on-year growth of approximately 11%. The Board of Directors of the Group has recommended the payment of a final dividend of HK10.0 cents per share for the year ended 31 August 2024, which, along with an interim dividend of HK9.6 cents per share, equates to a total annual dividend of HK19.6 cents per share and a dividend payout ratio of 30% for the year.From left to right: Mr. Yan Kwok Ting Sunny, Director of Investment, Corporate Finance & Investor Relations Department;Mr. Liu Yuk Tung, ChiefFinancial Officer; Ms. Liu Yi Man, Executive Director and Chief Executive Officer;Ms. Liu Wenqi, Chief Operating Officer;Fully embracing AI and continuously promoting the industry-education integrationOver the past year, the Group witnessed the groundbreaking development of the new generation of artificial intelligence technology. As a vocational education provider, the Group has developed in step with times, fully embracing AI in teaching, management and application. At present, all of its schools are actively promoting AI, fostering its popularity, with AI-embedded courses launched in seven colleges. Subsequent efforts will be made to promote those programmes to cover all faculties and students of all schools under the Group. Meanwhile, the Group actively responded to national policies, continuously deepened industry-education integration, and fully promoted the construction of industrial colleges, cooperating with multiple enterprises renowned in their respective industries to establish artificial intelligence and big data, digital trade, digitalised accounting and business services, research and tourism, jewelry, human resources and other industrial colleges. Those industrial colleges are all set up according to the Ministry of Education requirements for building modern industrial colleges that align with the country’s key industry development strategies, in order to nurture high-quality application-minded talent that emerging industries urgently need. In addition, the Group also entered into school-enterprise cooperation with numerous enterprises to build off-campus practice bases, further promoting the in-depth integration of education chains and industrial chains.Expanding exchange and cooperation of international education and deepening the connotations of international educationThe Group responded to the national advocacy for the opening up of education, “introduction of foreign schools”, and “international expansion of domestic schools”, continuously promoted the internationalisation of vocational education and expanded the partnership network with global renowned universities. By providing high-quality international programs and practice opportunities to students, the Group aims to cultivate innovative talents with global vision, to further raise the international influence of China’s vocational education. During the Reporting Period, the schools under the Group established in-depth cooperation with 51 foreign high schools in the United States of America, the United Kingdom, Canada, Japan and Australia, joining hands to create diverse high-quality international programmes. Furthermore, the Group comprehensively launched international study tours, organising 65 student and teacher study tours to France, Singapore, Hong Kong, China, Macau, China and other regions for short-term studies, with over 4,000 teachers and students participating during the Reporting Period. Looking forward, the Group will press on with deepening integration of its schools - domestic and international, strive to build a diversified international education cooperation network, actively promote Chinese vocational education to go global and build an internationally renowned Chinese vocational education brand.Consistently increasing investment in education to build a high-quality education brandThe Group has always adhered to the motto of "Establishing school of the century, Nurturing talents of the nation". Firmly believing that increasing investment in education is an important path towards high-quality education, the Group further expanded the new campus of Guangzhou Huashang College and Guangzhou Huashang Vocational College during the Reporting Period, which includes student dormitories, library, sports centre, teaching buildings and laboratories, providing solid support for future student enrollment and sustainable development of the Group. At the same time, it has kept increasing investment in building a high-quality teaching staff, which has expanded after the Guangzhou Huashang College and Guangzhou Huashang Vocational College established their Guangdong Province Doctoral Workstation respectively. The Group has launched a series of training workshops for teachers to continuously enhance their professionalism and practical teaching abilities, encouraging them to practice what they have learned and help improve school education and teaching quality. By introducing mentors from industries, it works together with enterprises in nurturing professional “dual-qualified” teachers and “dual-skilled” industry mentors, continuing to optimize the combined structure of full-time and part-time faculty teams. The in-depth and precise investment made by the Group in various areas crucial to strengthening school management has brought bountiful results. Guangzhou Huashang College placed third in scientific research competitiveness among private undergraduate colleges in China and has been designated as a key research base for humanities and social sciences among regular higher education institutions in Guangdong Province. Guangzhou Huashang Vocational College has been named a national exemplary vocational college, while the Urban Vocational College of Sichuan ranked second in China and first in Sichuan among Shanghai Ranking's 2024 Best Chinese Private Higher Vocational Colleges. These honors are a strong testament to the Group’s high-quality educational achievements.Looking ahead, the Group will continue to nurture innovative talent, focusing on such areas as industry and education integration, internationalization, and AI to keep up with industry and social development needs, increase investment in education, and keep building a high-quality education brand. It is committed to nurturing highly-skilled interdisciplinary corporate leaders for the country and industries around the world, while continuously making positive contributions to the sustainable development of vocational education.About Edvantage Group Holdings LimitedEdvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) is the largest private business higher education and vocational education group in the Greater Bay Area, and an early mover in education sector in pursuing international expansion, listed in Hong Kong Main Board on 16 July 2019. The total number of full-time student enrolments of the Group was approximately 96,000 as of 31 August 2024. Operated 9 private education institutions, namely, Guangzhou Huashang College (Applied Undergraduate), Guangzhou Huashang Vocational College (Higher Vocational Education) and Guangdong Huashang Technical School (Secondary Vocational Education) located in Guangdong Province, the PRC; Urban Vocational College of Sichuan (Higher Vocational Education) and Urban Technician College of Sichuan (Secondary Vocational Education) in Sichuan Province, the PRC; GBA Business School (GBABS) in Hong Kong, the PRC; Global Business College of Australia (GBCA) and Edvantage Institute Australia (EIA) in Australia; as well as Edvantage Institute (Singapore) (EIS) in the downtown of Singapore.While focusing on school operations, the Group also actively fulfil corporate social responsibility, extensively contributing to social welfare programmes including charity, poverty alleviation, education and revitalisation, in order to take the initiative in repaying society through action. Since its listing, the Group has made outstanding contributions in the field of ESG and has won the “Best ESG Innovation Award” from Zhitong Finance and the “Outstanding Enterprise for ESG Innovative Practice” from Gelonghui in 2024. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Institute of Directors ("HKIoD") announced the winners of its Award Series for Director Excellence (the "Awards") – comprising the long-established Directors of the Year Awards ("DYA") and the inaugural Climate Governance Awards ("CGA"), at its Annual Dinner yesterday at the Hong Kong Convention and Exhibition Centre. The event began with an opening speech by Dr Christopher To, Chairman of the HKIoD. Dr The Hon Moses Cheng Mo Chi, Non-official Member of the Executive Council of HKSARG, Mr Xu Wei Gang, Director General, Department of Economic Affairs, Liaison Office of the Central People's Government in HKSAR, Ms Salina Yan, JP, Permanent Secretary for Financial Services and the Treasury (Financial Services), and Dr Kelvin Wong, Chairman, Securities and Futures Commission ("SFC") and Chairman, Accounting and Financial Reporting Council ("AFRC") were invited as guests of honour. The response to the Awards submissions was overwhelmingly positive. After a lively discussion among the judges, this year's 19 winners, including directors and boards, were selected - all embodying the theme "Leading with Agility in an Era of Innovation". The awardees have demonstrated not only agility, but also the vision, courage and wisdom to lead against the backdrop of a demanding economic environment and prevailing geopolitical tensions. Moreover, they highlight the importance of having directors who can guide their companies in identifying the risks and opportunities associated with climate change, which are vital for ensuring the sustainability of the world and humanity.The Awardees of HKIoD Award Series* for Director Excellence 2024 are listed below:*Two series of Awards:- "DYA", acronym for "Directors Of The Year Awards"- "CGA", acronym for "Climate Governance Awards"In alphabetical order of names within categoryListed Companies CategoriesExecutive DirectorsDYAMr Chan Wai MingTown Ray Holdings LimitedCGAMs Clara Chan Yuen-shanLee Kee Holdings LimitedDYAMr Fu FanChina Pacific Insurance (Group) Co., LtdCGA Mr Li Wai LeungHengan Internationals Group Company LimitedMr Peter Wong Wai-YeeThe Hong Kong and China Gas Company LimitedDYA & CGAMr Yan Jianguo JPChina Overseas Land & Investment LimitedNon-Executive DirectorsDYA Dr Chung Shui Ming TimpsonChina Railway Group LimitedDr Tseng Shieng-chang CarterTCL Electronics Holdings LimitedProf Wang YijiangTCL Electronics Holdings LimitedBoardsDYA & CGAChina Resources Beer (Holdings) Company LimitedCGAHong Kong and China Gas Company LimitedDYA & CGAPing An Insurance (Group)Company of China, LtdCGAUnited Company RUSAL, international public joint-stock companyNon-listed Companies CategoriesExecutive DirectorsDYAMs Michelle ChanAS Watson IndustriesCGA Ir Prof Daniel M.ChengDunwell Technology (Holdings) Limited) (Dunwell Group)Ir Dr Cheng Sai Yau, VincentArup Fellow and Director of Climate and Sustainability in East AsiaDYAMr Orr Ka-yeung KevinWinner Medical (Hong Kong) LtdStatutory/ Non-profit-distributing Organisations CategoriesBoardsDYAHong Kong Tourism Board*In addition: recognition of Excellence in Board DiversityThe Institute of Internal Auditors Hong Kong*In addition: recognition of Excellence in Board DiversityThe guests of honour, special guests and officials to join the group photos together with the awardees (2nd row).About "HKIoD Award Series for Director Excellence"The HKIoD Award Series for Director Excellence is a project organised by The Hong Kong Institute of Directors ("HKIoD") and consists of two series of Awards.The first series, Directors Of The Year Awards, was inaugurated in 2001 as the first ever such Awards organised in Asia. As directors are ultimately responsible for corporate governance and leading the company in prosperity and integrity, the objectives of the Awards are to recognise outstanding boards and directors and to promote good practices in corporate governance and director professionalism. The Awards have become an annual project of impact in the community organised by HKIoD together with over 100 Project Partners. To date, 255 Awardees have been recognised for their achievements in demonstrating exemplary high standards in corporate governance and director practice.Inaugurated in 2024, Climate Governance Awards constitute the second series of HKIoD Awards with the objectives to recognise and inspire exemplary achievements in climate governance and to advocate climate action by directors. There are 10 awardees who have been acknowledged in the inaugural edition of the awards. It is critical time now for directors to address the risks and opportunities of climate change in board agendas and their governance role.Candidates are open to public nomination, with data processed in well-defined and stringent procedures, followed by interviews with independent consultants in utmost due diligence and finally selected by independent judges with high standards and fair judgment. Awards are presented by company categories, viz Listed Companies, Non-listed Companies and Statutory/Non-profit-distributing Organisations, and by capacities, viz Executive Directors, Non-Executive Directors and Boards.About The Hong Kong Institute of Directors ("HKIoD")The Hong Kong Institute of Directors ("HKIoD") is Hong Kong's premier body representing directors working together to advance corporate sustainability in creating long-term value for companies, their owners, stakeholders, humankind and Planet Earth through advocacy and standards-setting in corporate governance and director professionalism. Led by Founder Chairman Dr The Hon Moses Cheng, HKIoD was founded in 1997. Throughout the years, HKIoD is honoured to have the Chief Executive of HKSAR as the Institute's Patron. Membership of HKIoD comprises of directors from diverse industries and corporate types and includes Executive Directors, Non-Executive Directors and Independent Non-Executive Directors. With multi-culturalism and international perspectives, HKIoD organises activities that cover director training, seminars and forums, collective director voice, guideline establishment, public education, Award Series for Director Excellence, assessment of Corporate Governance Scorecard for listed companies etc.As a member body of the Global Network of Director Institutes ("GNDI"), HKIoD is committed to global collaboration in promoting good corporate governance and director professionalism. HKIoD is the appointed Host of the Hong Kong Chapter of Climate Governance Initiative, a global network that collaborates with the World Economic Forum in actively promoting directors' address of the risks and opportunities of climate change.For details please visit:http://www.hkiod.com|http://www.gndi.org|https://climate-governance.org/Media Enquiries:Award Series for Director Excellence:Strategic Public Relations Group LimitedThe Hong Kong Institute of DirectorsBrenda Chan+852 2114 4396/ brenda.chan@sprg.com.hkOdessa So +852 2889 4988/ odessa.so@hkiod.com Copyright 2024 ACN Newswire via SeaPRwire.com.

LONDON, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Spritzer has once again demonstrated its dominance in the bottled water industry by being named "Brand of the Year" in the national beverage division’s Water Category at the prestigious 2024–2025 World Branding Awards. The recognition marks Spritzer’s 10th consecutive win at the global awards, a testament to the brand’s enduring excellence in quality, branding, and consumer trust which further solidifies its position as Malaysia’s leading mineral water brand.Spritzer’s Head of Public Relations, Winnie Chin, accepting the Brand of the Year award under the national beverage division’s Water Category during the recent World Branding Awards at the Tower of LondonThe accolade was awarded by the World Branding Forum (WBF), a global non-profit organization devoted to advancing branding standards worldwide, at the annual World Branding Awards event which recognizes exceptional global and national brands across various categories. Winners in each category were evaluated through a rigorous process involving brand valuation, market research, and online public voting, showcasing a holistic assessment of brand strength and consumer trust. Most importantly, as the award evaluation relies heavily on consumer voting (70%), Spritzer’s continued wins over the years demonstrates the brand’s ability to consistently resonate with audiences and exceed customer expectations.Accepting the award on behalf of Spritzer during the awards ceremony held at the iconic Tower of London was Winnie Chin, Spritzer’s Head of Public Relations, who acknowledged the profound significance of this milestone: “We are honoured to receive this award for the 10th year running. Our achievements would not be possible without the unwavering support of our consumers, whose steadfast loyalty has made the Spritzer brand a household name. We also extend our gratitude to our partners for their collaboration and support and especially to our dedicated team for their hard work and creativity that have made this journey possible. We are deeply humbled and motivated to continue elevating our brand to greater heights, to build on Spritzer’s brand strength and commitment to excellence in all aspects of our company.”The award is a milestone that recognises Spritzer as a benchmark for consistency and adaptability to maintain brand trust and address emerging consumer needs in the ever-evolving market landscape. The company’s consistency, adaptability, and innovation have not only propelled it to the forefront of Malaysia’s bottled water industry but have also established it as a benchmark for quality, sustainability and innovation on a global stage. Spritzer’s decade-long winning streak at the awards exemplifies the brand’s commitment to producing high-quality natural bottled water and its reputation as a consumer-preferred brand.Building on this monumental achievement, Spritzer reaffirms its commitment to quality assurance as it continues to deliver bottled water with natural benefits and premium standards. The brand emphasises its dedication to sustainability goals and innovation as it continues to focus on advancing efforts to become a circular brand by 2030, aligned with global environmental initiatives, while leveraging cutting-edge technologies to introduce consumer-focused solutions to meet emerging needs.For more details about Spritzer, please visit our website at https://www.spritzer.com.my/.About Spritzer:Established in 1989, Spritzer Group has been a pioneer in providing Malaysians with natural mineral water sourced from a 440-acre green rainforest. Committed to innovation, Spritzer Group leads the Malaysian bottled water industry through manufacturing, distribution, marketing, and sales of its diverse product line. From renowned natural mineral water to refreshing non-carbonated fruit-flavoured drinks, each product is carefully crafted to meet consumer needs.Comprising eight business subsidiaries, Spritzer Group specializes in the production and distribution of silica-rich natural mineral water, sparkling natural mineral water, distilled drinking water, carbonated fruit-flavoured drinks, and non-carbonated fruit-flavoured drinks.With over 30 years of experience, Spritzer Group is Malaysia's largest and only listed bottled water producer. For more information, please visit www.spritzer.com.my. Copyright 2024 ACN Newswire via SeaPRwire.com.

SHANGHAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everest’s New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis. VELSIPITY(R) is an effective and convenient, once-daily, oral treatment for patients with moderately-to-severely active UC that has already been approved in the U.S. and E.U., and other countries, by Everest’s licensing partner, Pfizer. In Everest territories, the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China has approved the NDA for VELSIPITY(R) in April of this year and was implemented in the Guangdong-Hong Kong-Macau Greater Bay Area this October through the "Hong Kong and Macau Medicine and Equipment Connect" policy."Autoimmune disease is a core focus and a significant growth driver for our company. The number of UC patients in China is projected to double from 2019 to 2030 to approximately one million, highlighting the urgent need for novel treatments." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Previously, VELSIPITY(R) has already been approved in Macau, China, and was implemented in the Greater Bay Area through the connect policy. The company also plans to submit the NDA for approval by China’s National Medical Products Administration (NMPA) this year, with the aim of benefiting more Chinese patients as soon as possible."" This is an important advancement for etrasimod, bringing hope to patients in Hong Kong, China. This new-generation S1P receptor modulator is an oral, once-daily treatment that can provide patients with a chance for corticosteroid-free remission, mucosal healing, and rapid symptom relief, " said Prof. Wu Kaichun with the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial. “We hope China and other Asian countries can obtain approvals as soon as possible to benefit more patients."The acceptance of the NDA was based on results from the ELEVATE UC Phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) that evaluated the safety and efficacy of etrasimod 2 mg once-daily on clinical remission in UC patients with moderately to severely active UC who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy. Nearly two-thirds of patients in ELEVATE UC 52 and ELEVATE UC 12 were naïve to biologic or JAK inhibitor therapy, and these studies were also the only studies for advanced therapies for ulcerative colitis to include patients with isolated proctitis. Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod.Everest conducted a multicenter, randomized, double-blind and placebo-controlled Phase 3 trial of etrasimod in Asian countries, including mainland China, China Taiwan and South Korea. This is the largest Phase 3 trial of moderately-to-severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to treatment with etrasimod or placebo. The previously announced results of the induction period indicate that the clinical remission rate for patients treated with etrasimod 2mg was 25.0%, compared to 5.4% for those treated with placebo (difference 20.4%, p

上海, 2024年12月2日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布中国香港卫生署已正式受理伊曲莫德（VELSIPITY(R)）用于治疗中重度活动性溃疡性结肠炎成人患者的新药上市许可申请（NDA）。伊曲莫德是一款每日一次口服的一线先进疗法，不仅使用方便、疗效佳，而且具有良好的安全性特征。伊曲莫德已于去年10月和今年2月先后在美国和欧盟获得新药上市批准，同时，伊曲莫德也于今年4月获得中国澳门特别行政区药物监督管理局批准上市，并于今年10月通过"港澳药械通"政策在粤港澳大湾区落地。云顶新耀首席执行官罗永庆表示："我们非常高兴看到伊曲莫德的新药上市许可申请在中国香港获得正式受理。自身免疫性疾病是我们的重点关注领域和重要价值的潜在增长动力。到2030年，中国的溃疡性结肠炎患者人数预计将达到约100万人，超过2019年患者人数的一倍以上，存在迫切且巨大的未被满足的临床需求。伊曲莫德已在中国澳门获批，并通过"港澳药械通"政策率先在粤港澳大湾区落地。今年我们预计也将在中国大陆地区递交伊曲莫德的新药上市许可申请。期待伊曲莫德在更多地区获批，进一步扩大可及性，造福广大患者。"伊曲莫德亚太临床试验牵头研究者、世界胃肠病学会执行理事、亚太消化学会副主席、中国人民解放军空军军医大学附属西京医院吴开春教授表示："祝贺伊曲莫德取得的这一新进展，为中国香港的患者带来了希望。伊曲莫德具有良好的获益-风险特征，这种新一代S1P受体调节剂通过每日一次口服的治疗方案，可快速起效，并达到无激素缓解、黏膜愈合，可为中重度活动性溃疡性结肠炎成人患者提供先进的治疗选择。我们期待伊曲莫德在大中华区及其他亚洲国家早日获批，为患者带来福音。"伊曲莫德的申请是基于ELEVATE UC III期注册研究（ELEVATE UC 52和ELEVATE UC 12）的结果，该研究旨在评价既往对至少一种常规治疗、生物制剂或Janus激酶（JAK）抑制剂治疗失败或不耐受的中重度活动性溃疡性结肠炎患者，每日一次服用2mg 伊曲莫德的安全性和疗效。在ELEVATE UC 52和ELEVATE UC 12中，纳入了一半以上严重活动性溃疡性结肠炎患者（mMS≥7），并有近三分之一患者曾接受过生物制剂或JAK抑制剂治疗。伊曲莫德的UC研究也是迄今唯一纳入了孤立性直肠炎患者的UC研究。这两项随机、双盲、安慰剂对照研究均达到了所有主要和关键次要终点，安全性特征与既往研究一致。在ELEVATE UC 52研究中，第12周时，接受伊曲莫德治疗的患者临床缓解率为27.0%（安慰剂组7.0%, 差异20.0%，P

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC).The Phase Ia clinical trial of the second-generation GKA (HM-002-1005) was conducted in the United States in 40 subjects with Type 2 diabetes (T2D). This trial was randomized, double-blind, placebo-controlled, single-dose, focusing on safety, tolerability, and pharmacokinetics. The second-generation GKA is a novel molecular entity with optimized physicochemical properties, holding new patents, and serving as the prodrug of dorzagliatin (HMS5552). This study designed for once-daily oral administration. Its aim is to extend the drug's action duration in the body through sustained-release technology, enhance patient compliance, and prolong the stimulation of GLP-1 secretion in the intestines.The Single Ascending Dose (SAD) study demonstrates that HM-002-1005 tablets can be rapidly converted to HMS5552 in the human body, with minimal exposure level of prodrug in both blood and urine. The t1/2 (biological half-life) after a single dose of HM-002-1005 tablets was prolonged compared to dorzagliatin tablets. The Cmax of HMS5552 in plasma after a 184.5mg single dose is comparable to the plasma concentration of HMS5552 after a 75mg single dose of dorzagliatin tablet; likewise, the daily AUC of HMS5552 in plasma after a single dose of HM-002-1005 tablets is comparable to the exposure level of HMS5552 after a 75mg BID dose of dorzagliatin tablets. The research indicates that HM-002-1005 tablets are near-completely converted to HMS5552 in human, and its pharmacokinetic characteristics support for once-daily oral administration. The development of HM-002-1005 tablets not only contributes to enhancing patient medication adherence and effectively control blood glucose levels within 24 hours; meanwhile, it also offers the opportunity to explore the Maximum Tolerated Dose above 150mg daily to achieve better efficacy. The 75 mg BID dose regiment was developed under the concept of Minimum Therapeutic Effective Dose in Chinese T2D patients who suffered from an impairment of insulin secretion and significant reduction of early phase insulin. The different disease characters of T2D with obesity in western patient population would benefit dorzagliatin from its effects on GLP-1 secretion and improvement of insulin sensitivity.With the confirmation that the exposure level of HM-002-1005 tablets at 184.5mg is comparable to dorzagliatin tablets at 75mg (BID), we will further optimize the dosage form followed by a Multiple Ascending Dose (MAD) clinical development of the 2nd generation GKA in China and the United States.Dr. Li CHEN, founder and CEO of Hua Medicine, stated, “Hua Medicine has always been committed to treating Type 2 diabetes at its root cause by restoring patients’ ability to autonomously regulate blood glucose levels. Over the course of a decade, the Company has selected dosing and clinical research protocols that are safe and effective for the majority of Chinese diabetes patients, leading to the successful development of GKA and the clinical application of dorzagliatin. Building on this foundation, the Company will undergo a strategic upgrade by further exploring the therapeutic potential of GKA, enriching its product pipeline and seeking partners both domestically and internationally, in order to benefit a broader range of patients, expand into global markets, and effectively establish the brand identity of GKA medications while maximizing the commercial potential of our global first-in-class drugs.”About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC).The SENSITIZE study was initiated by Professor Juliana Chan, an international endocrinology specialist at The Chinese University of Hong Kong, as the lead researcher. It is the first clinical study in Asian populations to evaluate the impact of GKA on β-cell glucose sensitivity in the populations with varying degrees of impaired glucose tolerance using the technology of hyperglycemic clamp. The study aims to explore the impairment of glucokinase (GK) function and clinical characteristics in different types of glucose dysregulation, providing new scientific evidence on the pathophysiology of Asian Type 2 diabetes and the central role of GK in blood glucose regulation.The SENSITIZE 2 study results announced at CBIIC demonstrate that a single dose of dorzagliatin restores GK enzyme activity, significantly improving the second-phase insulin secretion and β-cell glucose sensitivity in individuals with impaired glucose tolerance (IGT) in hyperglycemic clamp study. In addition, the SENSITIZE 1 study previously reported at the 2022 ADA annual meeting showed that dorzagliatin directly restores the activity of GK mutants, leading to significant improvements in the second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2), and significantly enhance basal insulin secretion in newly diagnosed type 2 diabetes patients.Hua Medicine will continue to investigate β-cell glucose sensitivity improvement and incretin effect in response of repeated dose of dorzagliatin in individuals with intermediate hyperglycemia (IH) and Type 2 diabetes, in order to establish personalized intervention and treatment management plans for prediabetic and Type 2 diabetes patients.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.

上海, 2024年11月30日 - (亚太商讯 via SeaPRwire.com) - 华领医药（"公司"，香港联交所股份代号：2552.HK）今天在第九届中国医药创新与投资大会（The China BioMed Innovation and Investment Conference，以下简称CBIIC）上宣布，已经成功完成在美国开展的第二代葡萄糖激酶激活剂（GKA）的Ia临床研究。第二代GKA（HM-002-1005）Ia临床试验是在美国40例2型糖尿病（T2D）受试者中进行的随机、双盲安慰剂对照、单剂量、安全性、耐受性、药代动力学研究。第二代GKA是一种具有优化的理化性质的新分子实体，拥有新专利，为多格列艾汀（HMS5552）前药。该项研究设计为每日一次口服给药，旨在通过缓释技术来延长药物在体内的作用时间、改善患者依从性以及延长刺激肠道内GLP-1分泌的效果。这一单次剂量递增（SAD）研究结果显示，HM-002-1005片在人体内可迅速转化为HMS5552，前药在血浆和尿液中的暴露量极低。HM-002-1005片单次给药后的t1/2（生物半衰期）相较于多格列艾汀片延长。184.5mg单次给药后，血浆中HMS5552的Cmax与多格列艾汀片75mg单次给药后的血浆HMS5552浓度相当；同时，血浆中HMS5552的单日AUC与多格列艾汀片75mg一天两次给药后HMS5552的暴露水平相当。该研究表明，HM-002-1005片在人体内几乎完全转化为HMS5552，且其药代动力学特征支持每日一次口服给药方式。HM-002-1005片的开发不仅有利于提高患者服药的依从性，实现24小时内有效控制血糖；同时，也为探索每日150mg以上的最大耐受剂量提供了机会，以获得更好的治疗效果。多格列艾汀75mg每日两次（BID）剂量是根据最低有效治疗剂量的治疗理念，针对中国2型糖尿病患者普遍存在的胰岛素分泌缺陷和早相胰岛素分泌显著降低而开发的剂型。西方2型糖尿病患者具有不同的疾病特点，往往合并肥胖症状，多格列艾汀能够促进GLP-1分泌、改善胰岛素敏感性，有望为该患者群体带来新的获益。该研究结果确认HM-002-1005片184.5mg的暴露水平与多格列艾汀片75mg BID相当，公司将进一步优化剂型，在中国和美国进行第二代GKA的多次递增剂量（MAD）临床开发。华领医药创始人、CEO陈力博士表示："华领医药始终致力于通过修复患者血糖自主调控能力，从源头上治疗2型糖尿病。公司历经十年，选择了针对大多数中国糖尿病患者安全有效的用药剂量方案和临床研究方案，实现了GKA的成功开发和多格列艾汀的临床应用。在此基础上，公司将进行战略升级，通过继续探索GKA的用药潜力、丰富产品管线，在国内外寻求合作伙伴，惠及更多患者人群、拓展全球市场，更好地实现GKA药物的品牌建设和全球首创新药的商业价值。"关于华领华领医药（"本公司"）是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁(R)（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖稳态失调。2022年9月30日，华堂宁(R)已获得中国国家药品监督管理局（NMPA）的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于肾功能损伤的2型糖尿病患者的口服降糖药物。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com Copyright 2024 亚太商讯 via SeaPRwire.com.

上海, 2024年11月30日 - (亚太商讯 via SeaPRwire.com) - 华领医药（"公司"，香港联交所股份代号：2552.HK）今天在第九届中国医药创新与投资大会（The China BioMed Innovation and Investment Conference，以下简称CBIIC）上宣布，公司已经成功完成与香港中文大学Juliana Chan教授团队合作开展SENSITIZE研究，该研究为多格列艾汀改善β细胞葡萄糖敏感性的作用机制研究。SENSITIZE研究是由国际内分泌专家、香港中文大学Juliana Chan教授作为研究者发起的，首个在亚洲人群中采用高葡萄糖钳夹技术评估GKA对不同血糖调节受损人群的β细胞葡萄糖敏感性影响的临床研究，以探索不同葡萄糖激酶（GK）功能损伤类型在血糖失调方面的临床特征和干预手段，为研究亚洲T2D病生理及GK在血糖调控中的核心作用提供了新的科学依据。此次报告的SENSITIZE 2研究结果显示，采用高葡萄糖钳夹技术，多格列艾汀单次给药修复GK酶活性，显著改善葡萄糖耐量异常（IGT）人群的二相胰岛素分泌和β细胞葡萄糖敏感性。而此前在2022年美国ADA年会上报告的SENSITIZE 1研究结果显示，多格列艾汀可直接修复临床纳入的GK突变型活性，可以显著改善葡萄糖激酶单基因遗传突变糖尿病 (GCK-MODY或MODY-2)患者的胰岛素第二时相分泌和β细胞葡萄糖敏感性，可以显著改善初发2型糖尿病患者的基础胰岛素分泌。华领医药还将继续研究多格列艾汀多次给药对中间高血糖（IH）和2型糖尿病患者β细胞葡萄糖敏感性的修复作用，以及对肠促胰岛素的作用，从而建立糖尿病前期和2型糖尿病患者的个性化干预和治疗管理方案。关于华领华领医药（"本公司"）是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁（R）（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖稳态失调。2022年9月30日，华堂宁（R）已获得中国国家药品监督管理局（NMPA）的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于肾功能损伤的2型糖尿病患者的口服降糖药物。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com Copyright 2024 亚太商讯 via SeaPRwire.com.

- 天然气总销量达171.3亿立方米；- 累计接驳居民、工业和商业用户分别达到4,795.6万户、2.6万户及38.5万户；- 天然气顺价加快落地 销气毛差同比上涨0.02元/m³至0.59元/m³；- 增值服务经营性利润同比增长15.4%至10.0亿港元；- 财务状况稳健，财务资源丰富，自由现金流达22.2亿港元，备用银行授信及获批准的人民币债券总额约1,049.1亿等值港元；- 中期派息每股15.0港仙。财务摘要 截至9月30日止六个月 20242023变化千港元千港元%收入35,105,20236,049,154(2.6) 天然气销售19,641,83621,718,489(9.6) 燃气接驳2,027,0382,308,096(12.2) 工程设计、建设及施工 1,308,4871,056,41223.9 液化石油气（「LPG」）销售9,557,9768,421,66313.5 增值服务 2,012,9951,804,48611.6 其他业务556,870740,008(24.7)毛利5,855,6955,723,5732.3期间溢利2,263,9152,107,2037.4每股盈利（港仙）32.734.0(3.8)每股中期股息（港仙）15.015.0- 20249月30日20243月31日 变化千港元千港元%总资产153,473,528148,697,7243.2权益总额64,165,44260,747,3535.6银行结余及现金9,421,5978,280,33513.8香港, 2024年11月30日 - (亚太商讯 via SeaPRwire.com) - 国内具有领先地位的城市燃气营运商中国燃气控股有限公司（「中国燃气」或「集团」；股票编号：384）宣布其截至2024年9月30日止（「报告期」）之上半财年业绩。报告期内，为适时应对复杂多变的国际政治和经济形势，中国政府于九月开始推出稳定经济的措施。在一揽子有利政策的推动下，内地宏观经济有望持续回升向好，同时亦为提振天然气消费需求创造有利条件，城市燃气企业的盈利能力有望迎来修复，进入一个崭新发展期。此外，天然气上下游价格联动机制在全国范围内逐步落地，更多地区实现居民终端销售价格调整，销气毛差逐渐修复，进一步支撑天然气行业的健康及可持续发展。集团秉承"促回款、扩毛差、降费用、强组织、提品质、谋发展"的经营理念，积极探索创新业务的增长新路径，实现以燃气业务、增值服务、综合能源三大核心业务板块的协同发展。期内，集团录得营业额351.1亿港元，天然气售气总量达171.3亿立方米，自由现金流表现稳健，达22.2亿港元。董事会通过派付上半财年股息每股15.0港仙（2023/24年上半财年：15.0港仙），以回馈广大股东对集团的长期支持。加快天然气顺价落地，顺价比例及毛差进一步提高期内，集团抓住政策机遇，积极响应国家出台的天然气上下游价格联动机制及配气价格成本监审等政策，推动各地加快顺价，集团经营区域内新增20个市/县落实调价。截至2024年9月30日，集团累计完成居民气量顺价比例达62.2%，毛差修复至0.59元/m³，与去年相比取得稳步提升。期内，借助"老旧小区改造"和"瓶改管"等政策红利，新接驳904,232户居民用户、1,316户工业用户及24,906户商业用户。截至2024年9月30日，集团累计共为47,955,499户居民用户、25,792户工业用户及384,504户商业用户提供天然气服务，分别较去年同期增长约3.2%、10.7%和11.6%；集团城市燃气项目覆盖的可接驳户数达5,460万户。截至2024年9月30日，集团累计共于30个省、市、自治区取得662个拥有专营权的管道燃气项目，并拥有32个天然气长输管道、509座压缩/液化天然气加气站、一个煤层气开发项目及120个液化石油气分销项目。LPG业务保持高质量发展，持续优化纵向一体化协同作为中国规模最大、产业链最完整的综合性LPG运营服务商，集团业务覆盖全国22个省、市、自治区，目前运营5座液化石油气专用码头及6座大型石化产品仓储物流基地，码头年吞吐能力超过1,000万吨，总库容超过80万立方米。期内，集团实现销售液化石油气201.8万吨，销售收入总额达到95.6亿港元。集团持续优化纵向一体化协同，就上游而言，集团积极推进核心能力建设，提升国际贸易业务能力。期内，集团重构国际贸易团队和贸易风控体系，设立新加坡国际直采平台，在国际贸易业务方面取得实质性突破。于中游，集团推进仓储物流市场化运作，实现仓储物流资源整合，逐步提升仓储周转率，同时启动国内运贸平台建设，利用数字化赋能，扩大国内分销能力，从而提高国内分销与仓储物流效益。在下游端，集团推动创新业务模式与轻资产模式有效结合，通过迭代优化终端投资模式，丰富投资工具，助力终端业务高质量发展。增值服务营收利润双增长，未来发展空间巨大基于家庭场景，集团增值服务布局3大传统产品板块（厨房产品、安防产品、其它产品及服务）及4大新产品板块（电器、宜居、到家、优选）。目前增值服务业务遍及全国26个省、市、自治区，为用户提供产品及服务，不断增加用户覆盖，拓宽销售渠道。今年以来，中国消费市场保持稳定增长态势，政府出台多项政策鼓励家电以旧换新和家装消费品换新工程。集团把握政策机遇，于期内通过加快渠道建设、优化运营策略和强化终端赋能，实现增值服务收入同比增长11.6%至20.1亿港元；经营性利润同比增长15.4%至10.0亿港元。目前，集团通过不断深化传统渠道运营策略，优化产品结构，加快新业务拓展步伐，借助国家消费扶持政策，进一步扩大市场规模，未来发展空间巨大。积极探索综合能源业务商业模式，推进重点业务发展集团坚持以"绿色城市运营商"为战略定位，有效推进多业态融合、优化低能源成本综合方案以拓展市场、落地可长期发展的多赢商业模式。集团充分利用自身燃气项目的巨大市场和用户优势，通过外延式及内生性增长提升综合能源业务市场份额。期内，集团积极探索综合能源业务发展模式，锚定发展重点，投资及运营工商业用户侧储能、分布式光伏、锅炉节能、工商用户节能、建筑能效、充电桩、生物质能等业务。同时积极参与售电业务，并带动绿电绿证、碳排放因子库、虚拟电厂等业态快速扩充，为客户提供高效率的综合能源，满足客户对气、热、电、冷的不同需求。期内，储能及综合能效业务累计实现签约总装机容量318.4MWh，累计投建255.8MWh；售电业务交易量28.1亿度；绿证绿电业务完成销售8,196.4MWh。持续提升安全管理能力，积极推进老旧燃气管道等设施整改工作集团始终将安全管理视为核心任务，全面识别潜在风险，认真落实隐患整改，持续提升安全管理能力，为集团高质量发展营造安全稳定的环境。期内，集团通过开展专项治理工作，进一步规范基层员工操作，提升员工业务水平，并加强对燃气管道和相关设施关键信息的系统性收集，提升对管网资产的管理水平。同时，借助国家政策支持，集团积极推进老旧燃气管道和用户设施老化的更新改造与维护工作。此外，集团不断加强HSE体系审核认证及体系建设工作，建立健全集团双重预防机制管理模式，加强安全风险管控与隐患排查治理的闭环管理，并通过积极开展评级检查，有效提升了项目公司的安全管理水平。财务状况稳健截至2024年9月30日，集团总资产为1,534.7亿港元；银行结余及现金为94.2亿港元；期内集团通过执行严格的外币债务管理措施，及时合理地调整债务结构。集团一直积极与中国（包括香港）及外资银行建立长远合作关系，备用银行授信及获批准的人民币债券总额约1,049.1亿等值港元。行业发展及展望国际天然气价格在经历两年剧烈波动后，二零二四年以来重现平衡，供需端亦延续宽松态势。9月下旬开始，中国政府推出一系列稳经济、强信心的刺激政策，有助于经济复苏和房地产市场稳定，加上此前推出的"三大工程"、"超长期特别国债"、 "老旧管网更新"、"老旧小区改造"、"瓶改管"等利好燃气行业的政策，有利于稳固燃气行业根基。与此同时，各省市陆续发布和落实天然气上下游价格联动政策，有助于提升销气毛差，保障燃气企业的合理收益，促进天然气行业的健康长远发展。此外，全球低碳转型的浪潮不可阻挡，新能源和综合能源持续发展。集团将紧抓政策机遇，加快促进顺价落地，严控资本开支，推动数字化转型，进一步提升销气量及增值服务盈利水平，并全力推动综合能源项目发展，为国家经济发展提供"绿色"保障。集团主席兼总裁刘明辉先生表示："随着今年九月中国政府推出一系列旨在稳定市场的货币及财政政策以促进经济长期健康发展，相信更多具体、有力的稳经济政策将陆续出台，这些措施将提振资本市场信心，同时亦为中燃的业务发展提供良好的宏观环境。在宏观经济逐渐向好的大环境下，集团将发挥勇于创新变革的优良传统，不断优化业务模式，坚持高质量发展和可持续发展的策略，在不断做强集团燃气业务的基础上，继续深耕'客户导向'和'价值创造'，依托产业链延伸，拓展用户侧储能、生物质能等新业务，积极探索宜居、到家等增值服务新业态。同时，集团亦将把握机遇，紧跟政策、用好政策，缜密筹划，真正把国家政策红利转化为集团发展新动能，实现经营业绩与股东利益的双重增长。"有关中国燃气中国燃气控股有限公司（"中国燃气"，股票代号：384）是一家领先的燃气运营服务商，主要于中国从事投资、建设、经营城市燃气管道基础设施，向居民及工商业用户输送天然气和液化石油气，建设和经营车船用天然气加气站。同时，在庞大的燃气用户网络基础上，中国燃气打造了增值服务及综合能源并举的全业态发展结构。目前中国燃气在全国已拥有662个城镇的管道燃气专营权项目、32个天然气长输管道项目、509座压缩/液化天然气加气站，以及液化天然气等能源产品的进出口经营权，并拥有120个液化石油气分销项目。如欲获得更多中国燃气的资讯，请登入公司网址http://www.chinagasholdings.com.hk Copyright 2024 亚太商讯 via SeaPRwire.com.